Results 61 to 70 of about 240,836 (199)
Frontiers in Neurology, 2023 Patients with non-large vessel occlusion acute ischemic stroke (NL-AIS) on oral anticoagulants (OAC) constitute the biggest portion among those who cannot receive any potential-reperfusion treatment even if they appear early in the hospital.
Bartosz Karaszewski +12 more
doaj +1 more source
, 2022 Supplemental material, sj-docx-1-cath-10.1177_10760296221078842 for Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists by Vilmarie Rodriguez, Joseph ...
Joseph Stanek (12232496) +3 more
core +1 more source
Journal of Arrhythmia, Volume 42, Issue 5, October 2026.ABSTRACT The 2026 Asia Pacific Heart Rhythm Society (APHRS) Guidelines represent the first comprehensive APHRS guidelines dedicated to the management of atrial fibrillation (AF) and comprise four parts covering epidemiology, detection/screening and integrated care; stroke prevention; rate and rhythm control; and lifestyle risk factor and comorbidity ...
Tze‐Fan Chao +15 more
wiley +1 more source
, 2023 Given the paucity of comparative efficacy data and the difference in cost between andexanet-alfa and prothrombin complex concentrates (PCC), debates continue regarding optimal cost-effective therapy for patients who present with major bleeding associated
Lekura, Jona +6 more
core
medRxivAndexanet alfa was recommended by the National Institute for Health and Clinical Excellence (NICE) as an option in the management of major gastrointestinal bleeding in patients taking apixaban or rivaroxaban in May 2021. To assess the uptake of andexanet
Fisher L +11 more
europepmc +2 more sources
Emergency Medicine Australasia, Volume 38, Issue 5, October 2026.ABSTRACT Objective Many antidotes are relatively rare‐use, indication‐specific medicines with a variable evidence base. In Aotearoa New Zealand, there are no national statistics available on their use. This study aimed to characterize the numbers of cases and advice provided by the Aotearoa New Zealand National Poisons Centre (NZNPC) on the use of true
Eeva‐Katri Kumpula, William Boroughf
wiley +1 more source
JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 9, Issue 7, July 2026.Graphical abstract of consensus recommendations for clinical pharmacist integration into the acute stroke care team. ABSTRACT Clinical pharmacists are increasingly recognized as vital contributors to acute stroke care, yet their role remains inconsistently defined and underutilized across health care systems.
Brian W. Gilbert +18 more
wiley +1 more source
, 2018 Direct oral anticoagulants are associated with rates of major bleeding which are not negligible, albeit lower than those associated with vitamin K antagonists.
Sartori, M +3 more
core +1 more source
Andexanet Alfa: First Global Approval [PDF]
Drugs, 2018 Intravenous andexanet alfa [coagulation factor Xa (recombinant), inactivated-zhzo; Andexxa®] is a first-in-class recombinant modified factor Xa protein that has been developed by Portola Pharmaceuticals as a universal antidote to reverse anticoagulant effects of direct or indirect factor Xa inhibitors.
openaire +2 more sources
, 2021 OBJECTIVES: To combine evidence on andexanet alfa and prothrombin complex concentrates for factor Xa inhibitor-associated bleeding to guide clinicians on reversal strategies. DATA SOURCES: Embase, Pubmed, Web of Science, and the Cochrane Library.
Haytham M. A. Kaafarani +15 more
core +1 more source